studi
antibodi
focal
point
modern
biolog
medicin
sinc
earli
howev
progress
therapeut
antibodi
develop
slow
intermitt
recent
first
antibodi
therapi
murinederiv
murononab
acut
organ
reject
approv
us
food
drug
administr
fda
decad
milstein
georg
develop
method
isol
mous
monoclon
antibodi
hybridoma
cell
result
scientif
technolog
clinic
breakthrough
pace
therapeut
antibodi
discoveri
develop
acceler
antibodi
becom
major
drug
modal
two
dozen
therapeut
antibodi
clinic
hundr
develop
despit
progress
need
improv
exist
everi
level
antibodi
therapeut
provid
fertil
ground
protein
scientist
fulfil
dream
person
medicin
basic
scientif
discoveri
technolog
innov
keyword
monoclon
antibodi
person
medicin
therapeut
antibodi
antibodi
igg
isotyp
homodim
compos
two
heterodim
one
light
chain
one
heavi
chain
pioneer
research
robert
koch
kitasato
shibasaburo
emil
von
behr
paul
ehrlich
late
earli
centuri
treatment
infecti
diseas
serum
patient
recov
diseas
first
use
antibodi
therapeut
activ
compon
serum
describ
antibodi
antitoxin
magic
bullet
ehrlich
winau
et
al
crude
serum
therapi
later
modifi
isol
antibodi
serum
treatment
infecti
immun
diseas
known
intraven
immun
globulin
ivig
stangel
pul
despit
earli
success
serum
therapi
ivig
treatment
signific
progress
made
therapeut
antibodi
discoveri
develop
milstein
georg
develop
method
isol
mous
monoclon
antibodi
mab
hybridoma
cell
milstein
sinc
mab
fuel
breakthrough
discoveri
basic
research
also
develop
clinic
diagnost
reagent
high
throughput
drug
screen
importantli
lifesav
medicin
first
therapeut
mab
murononab
murinederiv
antibodi
acut
organ
reject
approv
us
food
drug
administr
fda
decad
discoveri
mous
hybridoma
technolog
thistlethwait
et
al
result
technolog
breakthrough
progress
therapeut
mab
field
acceler
therapeut
antibodi
shown
desir
safeti
profil
high
target
specif
affin
effici
disrupt
protein
protein
interact
becom
major
drug
modal
therapeut
antibodi
clinic
use
hundr
develop
reichert
valgearch
heterodim
homodim
link
inter
chain
disulphid
bond
stanfield
wilson
fig
light
heavi
chain
contain
variabl
constant
region
antigen
bind
complementar
determin
region
cdr
short
hypervari
amino
acid
sequenc
found
variabl
domain
light
variabl
light
vl
heavi
variabl
heavi
vh
chain
vh
vl
contain
three
pair
nonident
cdr
cdr
term
hypervari
domain
major
sequenc
variat
associ
antibodi
found
cdr
among
six
cdr
igg
molecul
greatest
variabl
fcregion
fragment
crystaliz
region
mab
resid
constant
region
heavi
chain
recruit
effector
cell
natur
killer
cell
macrophag
neutrophil
activ
complement
system
destroy
targetassoci
cell
function
refer
antibodydepend
cellular
cytotox
adcc
complementdepend
cytotox
cdc
four
addit
antibodi
isotyp
found
human
iga
igd
ige
igm
five
isotyp
share
common
theme
core
heterodim
build
unit
heavi
light
chain
igg
iga
igd
antibodi
isotyp
fc
region
compos
two
ident
protein
fragment
deriv
second
third
constant
domain
antibodi
two
heavi
chain
fc
region
igm
ige
contain
three
heavi
chain
constant
domain
polypeptid
chain
igg
isotyp
commonli
use
therapeut
applic
progress
antibodi
therapeut
driven
scientif
technolog
breakthrough
fig
therapeut
antibodi
develop
also
parallel
desir
industri
reduc
immunogen
immunogen
reduc
efficaci
therapeut
mab
sever
case
immunogen
caus
anaphylaxi
hypersensit
reaction
soon
approv
murinederiv
monoclon
antibodi
murononab
acut
organ
reject
thistlethwait
et
al
realiz
murinederiv
monoclon
antibodi
less
ideal
therapeut
due
high
immunogen
human
sever
strategi
make
antibodi
human
chimer
mab
morrison
et
al
cdr
graft
kettleborough
et
al
devis
reduc
human
antimous
antibodi
hama
respons
took
decad
first
chimer
mab
abciximab
hemostasi
approv
fda
fauld
sorkin
first
human
mab
zenapax
kidney
transplant
reject
approv
clinic
use
fda
vincenti
et
al
human
allevi
hama
respons
variou
degre
mani
drawback
becam
evid
exampl
human
process
technic
demand
process
may
result
reduc
antigen
bind
affin
decreas
efficaci
avoid
human
immun
respons
murinederiv
mab
overcom
technic
challeng
associ
human
murin
mab
two
major
approach
develop
gener
fulli
human
mab
first
approach
express
human
antibodi
fragment
bacteriophag
surfac
result
librari
contain
billion
uniqu
human
antibodi
fragment
screen
lead
vaughan
et
al
humira
first
fulli
human
mab
deriv
bacteriophag
display
antibodi
librari
approv
fda
treatment
rheumatoid
arthriti
weinblatt
et
al
second
approach
use
transgen
mice
produc
fulli
human
antibodi
russel
et
al
lonberg
achiev
replac
mous
nativ
antibodi
gene
human
counterpart
vectibix
antiegfr
antibodi
approv
colorect
cancer
therapi
first
fulli
human
antibodi
therapeut
deriv
transgen
mice
system
chua
cunningham
industri
trend
develop
human
like
antibodi
clinic
use
howev
immunogen
complex
biolog
process
predict
sole
human
content
antibodi
exampl
humira
fulli
human
antibodi
rel
high
incid
immunogen
bender
et
al
surprisingli
littl
differ
immunogen
antiantibodi
respons
human
chimer
mab
clinic
use
today
tabl
clearli
basic
clinic
research
need
develop
reliabl
paramet
predict
immunogen
therapeut
antibodi
prior
reach
clinic
access
diversifi
antibodi
sourc
paramount
success
discoveri
develop
antibodi
therapi
therapeut
antibodi
clinic
today
murin
origin
larg
due
earli
avail
mous
hybridoma
technolog
howev
entir
mous
antibodi
poor
pharmacokinet
human
due
human
antimous
antibodi
immun
respons
fig
reduc
immunogen
murin
antibodi
commonli
modifi
murinehuman
chimer
antibodi
human
antibodi
therapeut
applic
carter
valgearch
fig
later
transgen
mice
vitro
phage
display
employ
gener
fulli
human
therapeut
antibodi
circumv
immunogen
issu
associ
murin
sequenc
fig
hoogenboom
lonberg
jakobovit
et
al
lee
et
al
addit
phage
display
antibodi
fragment
also
display
yeast
feldhau
et
al
bacteria
harvey
et
al
mammalian
cell
smith
zauder
vitro
system
ribosom
hane
et
al
pro
con
variou
antibodi
platform
broadli
review
recent
ever
increas
demand
improv
tool
antibodi
drug
discoveri
lead
new
platform
technolog
exampl
human
rabbit
mab
develop
therapeut
news
yu
et
al
anoth
import
sourc
antibodi
human
antibodi
b
cell
repertoir
isol
human
mab
laborintens
endeavor
either
ebv
immort
hybridoma
fusion
construct
phagedisplay
antibodi
librari
vaughan
et
al
traggiai
et
al
li
et
al
roth
et
al
signific
technolog
breakthrough
b
lymphocyt
cultur
clone
report
recent
includ
analysi
hiv
flu
mab
natur
infect
vaccin
human
wrammert
et
al
jin
et
al
ogunniyi
et
al
scheid
et
al
walker
et
al
kwakkenbo
et
al
possibl
isol
human
memori
b
cell
sigg
igd
peripher
blood
mononuclear
cell
pbmc
importantli
cultur
prolifer
differenti
igg
secret
cell
isc
walker
et
al
singl
cell
cultur
vessel
engin
thu
enabl
highthroughput
screen
function
mab
jin
et
al
ogunniyi
et
al
new
method
b
cell
immort
ebv
infect
hybridoma
htert
report
kwakkenbo
et
al
addit
method
clone
igg
encod
gene
singl
b
cell
optim
wrammert
et
al
jin
et
al
ogunniyi
et
al
scheid
et
al
walker
et
al
kwakkenbo
et
al
technic
engin
accomplish
make
feasibl
isol
human
mab
broad
coverag
therapeut
target
therapeut
antibodi
full
length
igg
molecul
commonli
use
subisotyp
tabl
molecul
possess
sever
favor
characterist
structur
stabl
long
vivo
half
life
confer
fcmediat
biolog
effect
design
antibodi
therapeut
sometim
desir
diminish
abolish
adcc
cdc
function
retain
pharmacokinet
profil
case
benign
blocker
antibodi
purpos
use
antibodi
therapeut
tabl
protein
engin
appli
creat
fc
alter
properti
exampl
novel
engin
igg
isotyp
reduc
fc
function
recent
report
engin
base
isotyp
four
key
amino
acid
residu
chang
deriv
antibodi
overal
reduct
complement
fcg
receptor
bind
vitro
bind
analys
maintain
normal
vivo
serum
halflif
rhesu
monkey
addit
igg
molecul
antibodi
fragment
eg
fab
also
develop
therapeut
sandborn
et
al
rel
igg
molecul
antibodi
fragment
extens
penetr
tissu
particularli
solid
tumor
due
smaller
size
smaller
size
antibodi
fragment
advantag
access
therapeut
import
epitop
may
steric
hinder
addit
antibodi
fragment
may
manufactur
cost
effect
microbi
ferment
system
shorter
half
life
antibodi
fragment
extend
modifi
molecul
pegyl
absenc
fc
region
antibodi
fragment
may
lessen
side
effect
caus
interact
fc
immun
system
reopro
antigpiibiia
chimer
fab
prevent
blood
clot
angioplasti
first
antibodi
fragment
approv
clinic
use
us
fauld
sorkin
lucenti
fab
fragment
avastin
use
treatment
wet
agerel
macular
degener
kenneth
kert
recent
certolizumab
pegol
cimzia
pegyl
antibodi
fragment
approv
treatment
rheumatoid
arthriti
europ
current
antibodi
fragment
base
therapeut
activ
clinic
develop
nelson
reichert
antibodi
format
domain
antibodi
singl
chain
antibodi
also
explor
diagnost
therapeut
applic
holt
et
al
hollig
hudson
enev
et
al
pegyl
human
domain
antibodi
clinic
test
treatment
rheumatoid
arthriti
vk
vh
dab
enev
et
al
llama
nanoantibodi
target
von
willebrand
factor
develop
treatment
thrombosi
van
bockstael
et
al
antibodi
also
use
carrier
agent
small
molecul
toxin
radiolabel
isotop
guid
drug
specif
diseas
site
limit
undesir
effect
healthi
cell
applic
commonli
employ
oncolog
least
two
radiolabel
antibodi
zevalin
bexxar
approv
clinic
use
tabl
drug
difficult
administ
radiologist
oncologist
need
overse
administr
mylotarg
human
antibodi
conjug
calicheamicin
exampl
antibodi
use
carri
cytotox
payload
tabl
mani
challeng
still
exist
design
antibodi
drug
conjug
choic
linker
stoichiometri
conjug
chemistri
recent
advanc
result
linker
increas
stabil
bloodstream
allow
effici
payload
releas
within
tumor
cell
ducri
stump
increas
evid
suggest
conjug
antibodi
remain
effect
altern
mab
small
molecul
radiolabel
isotop
monotherapi
interest
note
earli
antibodi
therapeut
start
crude
polyclon
serum
therapi
ivig
major
today
antibodi
therapeut
targetspecif
monoclon
progress
made
develop
recombin
polyclon
antibodi
rpab
treatment
prophylaxi
human
diseas
pedersen
et
al
differ
ivig
rpab
rpab
mixtur
care
select
monoclon
antibodi
recombin
polyclon
antibodi
rpab
mimic
natur
human
immun
respons
human
bodi
produc
differ
type
antibodi
target
differ
epitop
antigen
polyclon
respons
may
better
chanc
neutral
diseas
target
singl
antibodi
one
major
challeng
face
approach
manufactur
antibodi
cocktail
consist
quantiti
qualiti
today
monoclon
antibodi
therapeut
function
singl
diseas
target
advantag
one
antibodi
molecul
bind
two
differ
target
sinc
mani
complex
diseas
result
multipl
mediat
multispecif
shown
natur
isol
antibodi
exampl
monoclon
ige
antibodi
bind
intend
antigen
dnp
hapten
also
bind
sever
unrel
compound
broad
rang
affin
jame
et
al
recent
antibodi
bind
vegf
report
bostrom
et
al
case
multispecif
confer
singl
bind
pocket
jame
et
al
bostrom
et
al
multispecif
antibodi
common
natur
construct
recombin
dna
method
kufer
et
al
wu
et
al
design
bispecifc
antibodi
activ
research
area
dualvariabledomain
immunoglobulin
dvdig
molecul
exampl
mani
design
bispecif
antibodi
wu
et
al
antibodi
larg
protein
subject
extens
complex
posttransl
modif
deamid
glycosyl
ntermin
pyroglutam
ctermin
lysin
truncat
methionin
oxid
posttransl
modif
profoundli
impact
physic
chemic
pharmacolog
properti
therapeut
antibodi
wang
et
al
oxid
methionin
residu
one
common
protein
degrad
pathway
includ
antibodi
addit
methionin
oxid
recombin
monoclon
antibodi
alter
interact
protein
protein
g
result
decreas
bind
affin
gazabulseco
et
al
spontan
nonenzymat
deamid
glutaminyl
asparaginyl
residu
alter
structur
function
therapeut
antibodi
potenti
result
decreas
bioactiv
well
alter
pharmacokinet
antigen
antibodi
therapeut
huang
et
al
among
variou
posttransl
process
glycosyl
broadest
effect
biolog
activ
protein
conform
stabil
solubl
secret
pharmacokinet
immunogen
therapeut
antibodi
arnold
et
al
exampl
differenti
igg
sialyl
may
provid
switch
innat
antiinflammatori
activ
steadyst
gener
adapt
proinflammatori
effect
upon
antigen
challeng
kaneko
et
al
low
fucos
level
antibodi
enhanc
neutrophiland
mononuclear
cellmedi
adcc
peipp
et
al
antibodi
glycoengin
one
activ
area
research
therapeut
antibodi
discoveri
develop
today
mimura
et
al
manufactur
mab
expens
larg
scale
facil
take
multipl
year
hundr
million
dollar
build
mammalian
cell
cultur
domin
product
platform
mab
therapeut
half
current
market
mab
express
chines
hamster
ovari
cho
cell
line
recombin
myeloma
hybridoma
still
use
antibodi
product
util
product
platform
limit
due
low
express
titer
instabl
cell
line
reduc
cost
antibodi
product
method
antibodi
express
bacteria
plant
transgen
anim
milk
egg
yeast
develop
certolizumab
pegol
exampl
mab
fragment
therapeut
made
bacteria
howev
antibodi
produc
e
coli
glycosyl
sever
limit
use
manufactur
platform
antibodi
specif
human
nglycan
structur
express
glycoengin
line
yeast
pichia
pastori
util
gener
platform
produc
recombin
antibodi
human
nglycosyl
develop
li
et
al
lin
et
al
antibodi
express
engin
chicken
egg
plant
zhu
et
al
cox
et
al
despit
signific
effort
cost
save
altern
antibodi
manufactur
platform
still
lack
part
due
effect
variou
express
host
antibodi
posttransl
modif
low
product
titer
clear
need
innov
technolog
breakthrough
reduc
manufactur
cost
therapeut
antibodi
limit
choic
express
host
purif
formul
storag
step
entir
manufactur
process
need
improv
bring
antibodi
therapeut
cost
competit
posit
small
molecul
drug
antibodi
engag
wide
rang
extracellular
drug
target
membran
bound
protein
circul
ligand
cytokin
tabl
even
though
antibodi
readili
cross
cell
membran
brain
blood
barrier
bbb
current
druggabl
target
access
antibodi
strohl
extracellular
signal
ec
drug
target
gener
modul
small
molecul
ec
target
typic
function
proteinprotein
interact
ec
protein
success
target
antibodi
therapeut
area
antibodi
strongest
presenc
term
market
product
development
research
oncolog
arthriti
immun
inflammatori
disord
aiid
monoclon
antibodi
clinic
use
develop
today
half
develop
oncolog
second
largest
therapeut
categori
aiid
area
infecti
diseas
fast
becom
major
diseas
area
antibodi
therapeut
emphasi
oncolog
aiid
therapeut
area
continu
antibodi
therapeut
develop
almost
diseas
area
central
nervou
system
cardiovascular
women
health
diabetesendocrinolog
hematolog
ophthalmolog
respiratori
diseas
strohl
antibodi
therapeut
repres
major
breakthrough
combat
human
diseas
improv
human
health
reflect
recent
trend
drug
discoveri
develop
nine
top
medicin
small
molecul
one
recombin
protein
short
eight
year
later
half
top
medicin
recombin
protein
antibodi
trend
continu
new
drug
variou
stage
clinic
develop
antibodi
despit
remark
progress
mani
scientif
technolog
clinic
challeng
remain
area
therapeut
antibodi
discoveri
develop
opportun
innov
exist
everi
level
access
difficult
antibodi
target
g
proteincoupl
receptor
novel
antibodi
sourc
format
cross
bbb
cell
membran
modifi
effector
function
improv
formul
deliveri
method
lower
cost
manufactur
name
aiid
arthriti
immun
inflammatori
disord
adcc
antibodydepend
cellular
cytotox
bbb
brain
blood
barrier
cdc
complementdepend
cytotox
cdr
complementar
determin
region
dnp
ec
extracellular
signal
fda
food
drug
administr
hama
human
antimous
antibodi
im
intramuscular
isc
igg
secret
cell
iv
intraven
ivig
intraven
immun
globulin
mab
mous
monoclon
antibodi
pbmc
peripher
blood
mononuclear
cell
rpab
recombin
polyclon
antibodi
sc
subcutan
vl
variabl
light
vh
variabl
heavi
